13F Holdings
中文EN

BLGO BIOLARGO, INC.

Chemicals & Allied Products · OTC · SEC CIK 880242 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-62.3%
TTM net income YoY-7.8%
TTM EPS YoY—
Revenue 3-yr CAGR-25.8%
Net income 3-yr CAGR—

Margins

Gross margin43.7%
Operating margin-355.4%
Net margin-260.6%
FCF margin—
EBITDA margin-349.9%

Returns

ROE-1,608.5%
ROA-129.8%
ROIC (approx.)—
Asset turnover0.50x

Leverage & solvency

Liabilities / assets165.9%
Debt / equity—
Current ratio0.60x
Interest coverage-14.79x

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$7.76M$17.78M$12.23M$5.88M$2.53M
Cost of revenue$4.36M$9.93M$6.08M$3.03M$1.43M
Gross profit$3.41M$7.85M$6.15M$2.86M$1.10M
R&D expense$2.59M$2.88M$2.28M$1.32M$1.37M
SG&A expense$11.77M$9.30M$8.06M$6.73M$6.17M
Operating income-$14.86M-$4.33M-$4.58M-$5.39M-$6.78M
Interest expense$540,000$71,000$91,000$53,000$234,000
Pretax income-$15.19M-$4.35M———
Income tax—$0$0——
Net income-$11.78M-$2.40M-$3.50M-$4.47M-$7.08M
EBITDA-$14.71M-$4.18M-$4.48M-$5.34M-$6.76M
EPS (basic)-0.04-0.01-0.01-0.02-0.03
EPS (diluted)————-0.03
Banking
Net interest income-$340,000-$33,000-$91,000-$53,000—
Balance sheet
Cash & equivalents$3.88M$3.55M$3.54M$1.85M$962,000
Receivables$615,000$3.17M$2.61M$1.06M$513,000
Inventory$310,000$330,000$153,000$120,000$241,000
Current assets$5.11M$7.14M$6.36M$3.15M$1.80M
PP&E, net$1.64M$1.74M$662,000$287,000$61,000
Intangibles———$4.86M$3.02M
Total assets$8.31M$10.51M$8.21M$4.86M$3.02M
Current liabilities$5.06M$2.65M$2.71M$1.58M$1.37M
Short-term debt—$66,000$66,000$100,000$314,000
Long-term debt$2.08M$1.08M$289,000$237,000$180,000
Total debt$2.08M$1.15M$355,000$337,000$494,000
Total liabilities$6.79M$4.46M$4.00M$2.85M$2.09M
Shareholders' equity$4.04M$8.85M$6.84M$4.88M$4.65M
Net debt-$1.80M-$2.40M-$3.18M-$1.51M-$468,000
Shares outstanding——292.95M278.46M—
Cash flow statement
Operating cash flow-$8.30M-$3.21M-$2.37M-$2.76M-$3.94M
Investing cash flow$435,000-$1.32M-$478,000-$271,000-$34,000
Financing cash flow$8.22M$4.44M$4.66M$3.96M$4.23M
Depreciation & amortization$145,000$155,000$103,000$45,000$20,000
Stock-based compensation$2.96M$2.06M$2.12M$2.07M$1.87M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.